Biodesix Inc. (BDSX)
NASDAQ: BDSXHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BDSX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $83.83M
- EPS (TTM)
- -$2.69
- Dividend yield
- None
- 52-week range
- 5.26 – 31.97
- Day range
- 7.50 – 8.45
- Volume / Avg
- 205.37K / 164.58K
- Beta
- —
- Shares outstanding
- 11.09M
52-week range
BDSX stock today
Shares of Biodesix (BDSX) finished lower on Nov 20 at $7.56, a drop of 8.92% or $0.74 per share, versus the S&P 500's 3.70% decline. Shares are 76.4% below their 52-week high of $31.97, set on Sep 28, 2026 and 43.7% above the 52-week low of $5.26, near the bottom of the past year's range. BDSX is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.7%.
Biodesix has posted a net loss over the last twelve months (EPS of -$2.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Biodesix
Company profileBiodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Scott Hutton
- Headquarters
- Louisville, CO
- Employees
- 334
- IPO year
- 2020
- Website
- biodesix.com
Financial highlights
Full financialsIn fiscal 2025, Biodesix generated $88.5 million in revenue, up 24.1% from fiscal 2024, its 3rd consecutive year of revenue growth. Biodesix reported a net loss of $35.3 million, compared with a loss of $42.9 million a year earlier. Operating margin was -31.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $88.50M | $71.32M | $49.09M | $38.21M | $54.51M |
| Growth | +24.08% | +45.30% | +28.46% | -29.89% | +19.64% |
| Net income | $-35.27M | $-42.93M | $-52.15M | $-65.45M | $-43.16M |
| EPS (diluted) | $-4.67 | $-6.64 | $-0.64 | $-1.55 | $-1.58 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$33.83+347.49%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.16 vs $-0.74
- Surprise
- -56.76%
BDSX news
All BDSX news- Friday 11/13 Insider Buying Report: BDSX, EQPTNasdaqBDSX, EQPT
- Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual MeetingGlobeNewswire
- Biodesix, Inc. Reports Third Quarter 2026 Financial Results and Revises Full-Year Revenue Guidance to $101 million to $103 millionNasdaqBDSX, UHAL.B
- Biodesix to Participate in Upcoming Investor ConferencesGlobeNewswire
- Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should KnowNasdaqBDSX, COR
- Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass EstimatesNasdaqLH, BDSX
- Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswire
- American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk StratificationGlobeNewswire
Biodesix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs BDSX |
| SERASera Prognostics Inc. Class A | 1.81 | -4.23% | $71.98M | vs BDSX |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs BDSX |
| BNRBurning Rock Biotech Limited ADR | 13.24 | -0.60% | $139.63M | vs BDSX |
| TLSITriSalus Life Sciences Inc. | 2.32 | +6.67% | $143.14M | vs BDSX |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs BDSX |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs BDSX |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs BDSX |
Indexes, lists and sector
Biodesix stock FAQ
What is Biodesix's stock price today?
BDSX last traded at $7.56 as of Nov 20, 4:00 PM EST, down 8.92% on the day. Prices are delayed at least 15 minutes.
Does Biodesix pay a dividend?
No. Biodesix does not currently pay a regular cash dividend.
Who is Biodesix's CEO?
Mr. Scott Hutton is the chief executive officer of Biodesix Inc., which has about 334 employees.
Has BDSX ever split its stock?
Yes. The most recent BDSX stock split was a 1-for-20 split on Sep 15, 2025.
What is the BDSX 52-week high?
The 52-week high for BDSX is $31.97 and the 52-week low is $5.26. The stock is currently 76.4% below its high.